TG4070

TG4070 – Phase 1 trial: Evaluation in Combination with Nivolumab in Resected Non-Small Cell Lung Cancer (NSCLC) Patients

 

TG4070

TG4070 is the second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate derived from our proprietary myvac® platform, expanding into non-small cell lung cancer (NSCLC). TG4070 is being evaluated in a Phase 1 trial in combination with nivolumab in patients with resected NSCLC following neoadjuvant nivolumab plus chemotherapy.

Discover TG4070

 

Phase 1: Safety and Tolerability

 

Key news
about Phase 1

Download the Press Release
Watch the replay of our KOL event

* please accept targeting cookies to allow replay

Despite advances in perioperative immunotherapy, approximately 65% of patients with NSCLC do not achieve a major pathological response* and remain at high risk of relapse.
TG4070 is designed for this high-risk population, with the potential to enhance and sustain anti-tumor immune responses when combined with checkpoint inhibitors.

*Disappearance of at least 90% of tumor cells

TG4070: Combining Transgene’s Proprietary AI-driven, Platform and Manufacturing Expertise

 

SNIPER

    TG4070 is powered by SNIPER (Specific Neoantigen Identification and Prediction of Elicited Response) Transgene’s proprietary AI-driven bioinformatics tool designed to identify and prioritize highly immunogenic neoantigens helping focus the INTV on the most relevant tumor-specific targets.

VacDesignR ®

    Fully integrated to myvac®, VacDesignR plays a key role in the design of myvac® candidates. Fully internalized, this bioinformatics tool enables optimization of the integration of the 30 selected neoantigens and helps improve both vaccine candidate design and the efficiency of recombinant viral vector production within the myvac® platform.

Cell line manufacturing

TG4070 is based on Transgene’s MVA (Modified Vaccinia Ankara) vector and is engineered to encode patient-specific neoantigens identified using SNIPER, Transgene’s proprietary neoantigen AI-driven selection tool. It is produced using a scalable cell line manufacturing process, designed to support robust and reliable supply.

Additional ressources